Alopecia Pipeline Review, H2 2019 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--
The “Alopecia - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides an overview of the Alopecia (Dermatology) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 17, 7, 1, 15 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/hmowmu
View source version on businesswire.com:https://www.businesswire.com/news/home/20191203006086/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 12/03/2019 05:25 PM/DISC: 12/03/2019 05:25 PM